A multi-institutional retrospective study of the efficacy and safety of immune checkpoint blockade for patients with non-small cell lung cancer and pre-existing autoimmune disease (NEJ047)

A multi-institutional retrospective study of the efficacy and safety of immune checkpoint blockade for patients with non-small cell lung cancer and pre-existing autoimmune disease (NEJ047) - NEJ047

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040512

Enrollment

100

Registered

2020-05-25

Start date

2020-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with non-small cell lung cancer and pre-existing autoimmune disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Advanced/Relapsed non-small cell lung cancer 2. Patients with pre-existing autoimmune disease 3. Either patients who received immune checkpoint inhibitors or not can be included.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
1. Ratio of acute exacerbation of AID in patients with NSCLC and AID who received ICB 2. Rate of serious immune related adverse events (irAE) in patients with NSCLC and AID who received ICB	—

Secondary

Measure	Time frame
1. Objective response rate (ORR) 2. Progression-free survival (PFS) 3. Overall survival (OS) 4. Time to treatment failure (TTF)	—

Countries

Japan

Contacts

Public ContactTetsuhiko Asao

Juntendo University Graduate School of Medicine Department of Respiratory Medicine

tasao@juntendo.ac.jp03-3813-3111

Outcome results